SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-282661
Filing Date
2022-11-10
Accepted
2022-11-10 16:26:03
Documents
12
Period of Report
2022-11-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d407323d8k.htm   iXBRL 8-K 21621
  Complete submission text file 0001193125-22-282661.txt   137986

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rare-20221110.xsd EX-101.SCH 2867
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE rare-20221110_lab.xml EX-101.LAB 17237
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rare-20221110_pre.xml EX-101.PRE 10820
6 EXTRACTED XBRL INSTANCE DOCUMENT d407323d8k_htm.xml XML 3221
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

IRS No.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 221377676
SIC: 2834 Pharmaceutical Preparations